Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,170,127 papers from all fields of science
Search
Sign In
Create Free Account
tasosartan
Known as:
5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one
, taso-sartan
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Angiotensin II Type 1 Receptor Blockers
Pyrimidines
Tetrazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction
V. Lee
,
D. Rhew
,
M. Dylan
,
E. Badamgarav
,
G. Braunstein
,
S. Weingarten
Annals of Internal Medicine
2004
Corpus ID: 46345264
Angiotensin-receptor blockers (ARBs) were first introduced into the marketplace in the early 1990s and have been used to treat…
Expand
Review
2001
Review
2001
Pharmacology of AT 1 -receptor Blockers
T. Unger
Blood pressure. Supplement
2001
Corpus ID: 45314205
Angiotensin II mediates its haemodynamic effects by binding to specific cell-surface receptors. In humans, two receptor subtypes…
Expand
Review
2000
Review
2000
Angiotensin II-receptor antagonists: an overview.
R. Dina
,
M. Jafari
American journal of health-system pharmacy : AJHP…
2000
Corpus ID: 51737
Angiotensin II (AT-II)-receptor antagonists are reviewed. Research focused on blocking the renin-angiotensin system (RAS) led to…
Expand
2000
2000
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
M. Maillard
,
J. Rossat
,
H. Brunner
,
M. Burnier
The Journal of pharmacology and experimental…
2000
Corpus ID: 22253521
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its…
Expand
Review
1999
Review
1999
Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.
P. Timmermans
Hypertension research : official journal of the…
1999
Corpus ID: 9727638
Acceptance of the notion that physiologically specific interruption of the renin-angiotensin-aldosterone system (RAAS) is of…
Expand
1999
1999
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
J. Hines
,
S. Fluharty
,
R. Sakai
European journal of pharmacology
1999
Corpus ID: 41354529
Review
1999
Review
1999
Pharmacological properties of angiotensin II receptor antagonists.
P. Timmermans
The Canadian journal of cardiology
1999
Corpus ID: 24694991
The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists…
Expand
1998
1998
Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.
J. Ellingboe
,
M. Collini
,
+8 authors
J. Bagli
Journal of medicinal chemistry
1998
Corpus ID: 20725718
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist…
Expand
1998
1998
Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients
C. Rhéaume
,
P. Waib
,
Y. Lacourciére
,
J. Cléroux
Journal of hypertension
1998
Corpus ID: 9043650
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal…
Expand
Review
1997
Review
1997
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
H. Brunner
American journal of hypertension
1997
Corpus ID: 13793488
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE